ENDRA Life Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ENDRA Life Sciences Inc. on August 16, 2024. The filing reports on a material corporate action approved by stockholders at the Annual Meeting held on August 6, 2024, and subsequently authorized by the Board of Directors.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a capital structure modification.
Material Changes
- Reverse Stock Split: The Company implemented a one-for-fifty reverse stock split.
- Effective Date: The split became effective at 12:01 a.m. Eastern Time on August 20, 2024.
- Share Count Reduction: The number of authorized common shares was reduced from 1,000,000,000 to 20,000,000.
- Trading Details: Common stock began trading on a split-adjusted basis under a new CUSIP (29273B 401).
- Fractional Shares: No fractional shares were issued; fractional interests were rounded up to the next whole share.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard disclosure regarding the amendment to the Certificate of Incorporation. The primary purpose is to disclose the execution of the reverse stock split.
Key Facts for Investor Verification
- Verify the new CUSIP number (29273B 401) for trading purposes effective August 20, 2024.
- Confirm the one-for-fifty split ratio applied to existing holdings.
- Check brokerage statements for the rounding up of fractional shares to whole shares.
- Review the Amendment to the Certificate of Incorporation (Exhibit 3.1) for complete legal terms.